EyePoint Plc (EYPT)
17.76
+0.70
(+4.07%)
USD |
NASDAQ |
Feb 25, 16:00
17.76
0.00 (0.00%)
After-Hours: 16:03
EyePoint Research and Development Expense (Quarterly) : 47.75M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 1.481B |
| Ocular Therapeutix, Inc. | 50.80M |
| Viking Therapeutics, Inc. | 153.46M |
| Janux Therapeutics, Inc. | 34.63M |
| Tango Therapeutics, Inc. | 30.26M |